BAKER BROS ADVISORS LLC 13D and 13G filings for BioCryst Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:21 pm Sale |
2023-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
BAKER BROS ADVISORS LLC | 10,204,089 4.980% |
-8,980,705 (-46.81%) |
Filing |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
BAKER BROS ADVISORS LLC | 19,184,794 9.950% |
720,050 (+3.90%) |
Filing |
| 2022-02-14 4:15 pm Purchase |
2021-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
BAKER BROS ADVISORS LLC | 18,464,744 9.950% |
285,863 (+1.57%) |
Filing |
| 2021-02-16 4:53 pm Purchase |
2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
BAKER BROS ADVISORS LLC | 18,178,881 9.990% |
2,303,756 (+14.51%) |
Filing |